Başer, Onur

Profile Picture
Profile URL
https://hdl.handle.net/20.500.11779/2820
Name Variants
Job Title
Email Address
basero@mef.edu.tr
Main Affiliation
04. Faculty of Economics, Administrative and Social Sciences
Status
Former Staff
Website
ORCID ID
0000-0001-7447-5672
Scopus Author ID
Turkish CoHE Profile ID
Google Scholar ID
WoS Researcher ID
JUE-8293-2023

Sustainable Development Goals

2

ZERO HUNGER
ZERO HUNGER Logo

0

Research Products

16

PEACE, JUSTICE AND STRONG INSTITUTIONS
PEACE, JUSTICE AND STRONG INSTITUTIONS Logo

1

Research Products

1

NO POVERTY
NO POVERTY Logo

0

Research Products

11

SUSTAINABLE CITIES AND COMMUNITIES
SUSTAINABLE CITIES AND COMMUNITIES Logo

0

Research Products

7

AFFORDABLE AND CLEAN ENERGY
AFFORDABLE AND CLEAN ENERGY Logo

0

Research Products

10

REDUCED INEQUALITIES
REDUCED INEQUALITIES Logo

10

Research Products

3

GOOD HEALTH AND WELL-BEING
GOOD HEALTH AND WELL-BEING Logo

44

Research Products

6

CLEAN WATER AND SANITATION
CLEAN WATER AND SANITATION Logo

0

Research Products

9

INDUSTRY, INNOVATION AND INFRASTRUCTURE
INDUSTRY, INNOVATION AND INFRASTRUCTURE Logo

0

Research Products

12

RESPONSIBLE CONSUMPTION AND PRODUCTION
RESPONSIBLE CONSUMPTION AND PRODUCTION Logo

0

Research Products

5

GENDER EQUALITY
GENDER EQUALITY Logo

0

Research Products

14

LIFE BELOW WATER
LIFE BELOW WATER Logo

0

Research Products

13

CLIMATE ACTION
CLIMATE ACTION Logo

0

Research Products

15

LIFE ON LAND
LIFE ON LAND Logo

0

Research Products

8

DECENT WORK AND ECONOMIC GROWTH
DECENT WORK AND ECONOMIC GROWTH Logo

0

Research Products

17

PARTNERSHIPS FOR THE GOALS
PARTNERSHIPS FOR THE GOALS Logo

2

Research Products

4

QUALITY EDUCATION
QUALITY EDUCATION Logo

0

Research Products
This researcher does not have a Scopus ID.
Documents

0

Citations

0

Go to WoS profile
Scholarly Output

97

Articles

27

Views / Downloads

17926/93164

Supervised MSc Theses

0

Supervised PhD Theses

0

WoS Citation Count

398

Scopus Citation Count

438

WoS h-index

12

Scopus h-index

13

Patents

0

Projects

0

WoS Citations per Publication

4.10

Scopus Citations per Publication

4.52

Open Access Source

22

Supervised Theses

0

JournalCount
Value in Health32
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting.18
International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual European Congress5
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting4
American Heart Association (AHA) Scientific Sessions 20152
Current Page: 1 / 8

Scopus Quartile Distribution

Competency Cloud

GCRIS Competency Cloud

Filters

2014 - 2019942020 - 20213
Reset filters

Settings

Scholarly Output Search Results

Now showing 1 - 10 of 97
  • Thumbnail Image
    Conference Object
    Evaluating the Economic Burden and Health Care Utilization of Coronary Artery Disease in the Us Medi-Cal Population
    (2016) Zhang, Q; Zhao, Y; Keshishian, A; Xie, L; Yuce, H; Başer, Onur
    ...
  • Thumbnail Image
    Conference Object
  • Thumbnail Image
    Conference Object
    Spatial Distribution of the Total Number of Medical Devices in Turkey: a Classification Analysis
    (2016) Cinaroğlu, S.; Başer, Onur
    Objectives: The unbalanced distribution of medical technologies and devices between rural and urban areas is a major problem for developing countries including Turkey. After the establishment of Public Hospital Unions (PHUs) in Turkey, legislative changes were made to improve the autonomy of public hospitals. This study utilizes spatial analysis to assess the distribution of medical device use in Turkey using PHUs as a decision making unit. Methods: Data from the PHUs’ statistics year book for the year 2014 was assessed. The total number of PHUs is 89. A Hierarchical cluster analysis was performed to classify PHUs according to the total number of medical devices. The Euclidean distance measure and Wards methods were used in the analysis for classification. Results: Study results show that, in Turkey, PHUs were categorized into two clusters based on the total number of medical devices available. Regarding the spatial distribution of the clusters, the first cluster represents PHUs in rural areas, and the second represents PHUs located in urban areas of Turkey. PHUs representing large cities with high population density were included in one cluster, and all other PHUs were included in the second. Statistical test results indicated that the two clusters differ according to the total number of magnetic resonance imaging (MRI: t= -14.10, p< 0.01), computed tomography (CT) scan (t= -15.75, p< 0.01), mammography (t= -11.40, p< 0.01), ultrasonography (t= -14.62, p< 0.01), and electrocardiography (EKG; t= -12.29, p< 0.01) equipment available. Conclusions: It is advisable for health policy makers and health technology assessment authorities in Turkey to focus on the differences between rural and urban areas of the country when determining the need for medical devices.
  • Thumbnail Image
    Conference Object
    Trends in Prevalence and Incidence Rates of Type 2 Diabetes Mellitus in the Medicare Population
    (2015) Xie, L; Wang, Y; Tan, H; Ogbomo, A; Başer, Onur; Yuce H.
    ...
  • Thumbnail Image
    Conference Object
  • Thumbnail Image
    Conference Object
    Demographic and Clinical Characteristics of Patients With Polycythemia Vera (pv) in the Us Veterans Population
    (2016) Parasuraman S; Yu J; Paranagama D; Shrestha S; Wang L,; Başer, Onur
    ...
  • Thumbnail Image
    Article
    Citation - WoS: 15
    Citation - Scopus: 15
    Economic Outcomes in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide or Abiraterone Acetate Plus Prednisone
    (Springer, 2020) Lechpammer, Stanislav; Ramaswamy, Krishnan; Wang, Li; Mardekian, Jack; George, Daniel J.; Sandin, Rickard; Schultz, Neil M.; Başer, Onur; Huang, Ahong
    Introduction: Prostate cancer (PC) is the second leading cause of cancer death among US men and accounts for considerable healthcare expenditures. We evaluated economic outcomes in men with chemotherapy-naı¨ve metastatic castration-resistant PC (mCRPC) treated with enzalutamide or abiraterone acetate plus prednisone (abiraterone). Methods: We performed a retrospective analysis on 3174 men (18 years or older) utilizing the Veterans Health Administration (VHA) database from 1 April 2014 to 31 March 2018. Men with mCRPC were included if they had at least one pharmacy claim for enzalutamide or abiraterone (first claim date = index date) following surgical or medical castration, had no chemotherapy treatment within 12 months prior to the index date, and had continuous VHA enrollment for at least 12 months pre- and post-index date. Men were followed until death, disenrollment, or end of study and were 1:1 propensity score matched (PSM). All-cause and PC-related resource use and costs per patient per month (PPPM) in the 12 months post index were compared between matched cohorts. Results: We identified 1229 men with mCRPC prescribed enzalutamide and 1945 prescribed abiraterone with mean ages of 74 and 73 years, respectively. After PSM, each cohort had 1160 patients. The enzalutamide cohort had fewer all-cause (2.51 vs 2.86; p\0.0001) and PC-related outpatient visits (0.86 vs 1.03; p\0.0001), with corresponding lower all-cause ($2588 vs $3115; p\0.0001) and PC-related ($1356 vs $1775; p\0.0001) PPPM outpatient costs compared with the abiraterone cohort. Allcause total costs (medical and pharmacy) PPPM ($8085 vs $9092; p = 0.0002) and PC-related total costs PPPM ($6321 vs $7280; p\0.0001) were significantly lower in the enzalutamide cohort compared with the abiraterone cohort. Conclusions: Enzalutamide-treated men with chemotherapy-naı ¨ve mCRPC had significantly lower resource utilization and healthcare costs compared with abiraterone-treated men. Plain Language Summary: Plain language summary available for this article.
  • Thumbnail Image
    Conference Object
  • Thumbnail Image
    Conference Object
    Examining the Incidence and Prevalence of Alcohol Dependence Among Us Veteran Patients
    (2016) Bashyal, R; Du, H; Wang, L; Başer, Onur
    ...
  • Thumbnail Image
    Article
    Creating National Weights for a Patient-Level Longitudinal Database
    (2016) Başer, Onur; Li Wang; Maguire J.
    To create a nationally-representative estimate from longitudinal data by controlling for sociodemographic factors and health status. The Agency for Healthcare Research and Quality’s (AHRQ) Medicare Expenditures Panel Survey (MEPS) was used as the basis for adjustment methodology. MEPS is a data source representing health insurance coverage cost and utilization, and comprises several large-scale surveys of families, individuals, employers, and health care providers. Using these data, we created subset populations. We then used multivariate logistic regression to construct demographics and case-mix-based weights, which were applied to create a population sample that is similar to the national population. The weight was derived using the inverse probability of the weighting approach, as well as a raking mechanism. We compared the results with the projected number of persons in the US population in the same categories to examine the validity of the weights. The following variables were used in the logistic regression: Age group, gender, race, location, income level and health status (Charlson Comorbidity Index scores and chronic condition diagnosis). Relative to MEPS data, patients included in the private insurance data were more likely to be male, older, to have a chronic condition, and to be white (p=0.0000). Adjusted weighted values for patients in the commercial group ranged from 15.47 to 36.36 (median: 16.91). Commercial insurance and MEPS data populations were similar in terms of their socioeconomic and clinical categories. As an outcomes measure, the predicted annual number of patients with prescription claims from private insurance data was 6 963 034. The annual number of statin users were predicted as 6 709 438 using weighted MEPS data. National projections of large-scale patient longitudinal databases require adjustment utilizing demographic factors and case-mix differences related to health status.